Background: The outcome in children and adolescents with high-risk (HR) acute myeloid
leukemia (AML) is still unsatisfactory. Therefore, in study AML-BFM 2004 we aimed to …

Abstract Cytarabine (1000 mg/m 2/d intravenous for 5 d) and clofarabine (40 mg/m 2/d
intravenous for 5 d) were given every 28 days to 9 children with relapsed acute myeloid …

目的评价两种诱导缓解治疗方案(3+ 7 方案和3+ 10 方案) 治疗儿童急性髓系白血病(AML)
的疗效. 方法回顾分析2010 年1 月至2015 年1 月接受化疗的AML 患儿100 例 …

Despite remarkable improvements in the treatment of pediatric acute leukemia (AL) over the
last decades, relapse still carries a poor prognosis with significant morbidity and mortality …

Akutna mijeloična leukemija u djece: analiza kliničkih i bioloških značajki te rezultata liječenja u
Klinici za pedijatriju Page 1 http://hrcak.srce.hr/medicina medicina fluminensis 2016, Vol. 52, No …

The human blood production system is a highly regulated process. The hematopoietic stem
cells, capable of long-term self-renewal, give rise to the daily production of billions of new …

RESUMEN “Frecuencia de leucemia mieloide aguda en pacientes pediátricos de un
hospital de tercer nivel de occidente de México” Antecedentes: La leucemia mieloide aguda …

Introduction Acute myeloid leukaemia (AML) is the second haematological malignancy in
the paediatric population, and one of the leading causes of childhood cancer mortality …

Background Acute myeloid leukemia (AML) and hyperleukocytosis have an unfavorable
prognosis, but the impact of hyperleukocytosis on the prognosis of pediatric AML remains …

Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade®) is an emerging …